News & Updates
Filter by Specialty:
Statins help prevent breast cancer recurrence in Asians
Breast cancer patients who take statins see a sharp decline in the risk of tumour recurrence, according to a recent Singapore study. This protective effect seems to be stronger in ER+ and HER2- malignancies.
Statins help prevent breast cancer recurrence in Asians
07 Apr 2022Prophylactic anticoagulants, pharmacy oversight lower VTE risk in multiple myeloma
Treatment with a guideline-based thromboprophylaxis in multiple myeloma patients and the addition of pharmacy oversight to risk assessment can help reduce the risk of venous thromboembolism (VTE), suggests a recent study.
Prophylactic anticoagulants, pharmacy oversight lower VTE risk in multiple myeloma
06 Apr 2022Relapsed/refractory multiple myeloma patients burdened with poor survival, high costs
Patients with relapsed/refractory multiple myeloma (RRMM) are at greater risk of adverse events (AEs), have low overall survival (OS), and suffer a substantial economic burden, reports a study, which suggests the need for effective treatment options.
Relapsed/refractory multiple myeloma patients burdened with poor survival, high costs
06 Apr 2022COPD, smoking aggravate complication risk after lung cancer resection
Smoking and chronic obstructive pulmonary disease (COPD) worsen the risk of postoperative pulmonary complications after lung cancer resection, a recent study has found. Focusing on COPD treatment, rather than smoking cessation alone, may be a more optimal approach to improve postoperative outcomes in this population.
COPD, smoking aggravate complication risk after lung cancer resection
03 Apr 2022Tislelizumab produces long-term benefits in relapsed, refractory classical Hodgkin lymphoma
Treatment with the antiprogrammed cell death protein 1 (anti–PD-1) monoclonal antibody tislelizumab yields high response rates in relapsed or refractory classical Hodgkin's lymphoma, with a similar toxicity profile as other anti–PD-1 therapies, as shown in the extended results of a phase II trial.